Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Price Regulator Urged To Cut New Price Approvals To 30 Days

This article was originally published in PharmAsia News

Executive Summary

India's National Pharmaceutical Pricing Authority is being pressured by other parts of the government to cut in half the clearance time for pricing changes, which now take 60 days. The Department of Chemicals and Petrochemicals requested reduction of the approval period to 30 days to satisfy industry complaints about the recent increase in prices of bulk drugs from China. Many Indian drug makers have been applying for permission to raise prices, including those who make bulk drugs. Some industry groups urge a 20 percent increase in the consumer drugs, bulks by 25 percent. (Click here for more

You may also be interested in...



Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.

Health And Wellness Product Trademark Review 10 December, 2019

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
UsernamePublicRestriction

Register

SC069397

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel